A5075650598- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- Immune Cell Function and Interaction
- Cancer Research and Treatments
- Ubiquitin and proteasome pathways
- CAR-T cell therapy research
- T-cell and B-cell Immunology
- Nanoplatforms for cancer theranostics
- Telomeres, Telomerase, and Senescence
- Immunodeficiency and Autoimmune Disorders
- Cancer Cells and Metastasis
- RNA Interference and Gene Delivery
- Renal cell carcinoma treatment
- Virus-based gene therapy research
- Phagocytosis and Immune Regulation
- Immune cells in cancer
- Renal Diseases and Glomerulopathies
- Metabolism, Diabetes, and Cancer
- Reproductive System and Pregnancy
- Cancer, Hypoxia, and Metabolism
- vaccines and immunoinformatics approaches
- Cytomegalovirus and herpesvirus research
- PI3K/AKT/mTOR signaling in cancer
- Chronic Lymphocytic Leukemia Research
- Renal and related cancers
Swiss Cancer Center Léman
2023
École Polytechnique Fédérale de Lausanne
2023
Université Bourgogne Franche-Comté
2016-2018
Inserm
2012-2018
Biotherapy of Genetic Diseases, Inflammatory Disorders and Cancers
2017
Centre Hospitalier Universitaire de Besançon
2016
Université de franche-comté
2013-2014
Établissement Français du Sang
2013
Bipar
2013
Observatoire des Sciences de l’Univers Terre Homme Environnement Temps Astronomie
2013
Despite the remarkable success of immune checkpoint blockade (ICB) therapy, most cancer patients still do not respond. We now find that immunotherapy can induce stem-like properties in tumors. Using mouse models breast cancer, we observe stem cells (CSCs) show only enhanced resistance to T cell cytotoxicity, but interferon gamma (IFNγ) produced by activated directly converts non-CSCs CSCs. IFNγ enhances several CSC phenotypes, such as chemo- and radiotherapy metastasis formation. identified...
To evaluate CD4(+) helper functions and antitumor effect of promiscuous universal cancer peptides (UCP) derived from telomerase reverse transcriptase (TERT).To the widespread immunogenicity UCPs in humans, spontaneous T-cell responses against were measured various types cancers using proliferation ELISPOT assays. The humanized HLA-DRB1*0101/HLA-A*0201 transgenic mice used to study effects on CTL responses. UCP-based therapeutic vaccine was evaluated HLA-A*0201-positive B16 melanoma that...
Abstract The rapalogs everolimus and temsirolimus that inhibit mTOR signaling are used as antiproliferative drugs in several cancers. Here we investigated the influence of rapalogs-mediated immune modulation on their antitumor efficacy. Studies metastatic renal cell carcinoma patients showed promoted high expansion FoxP3+Helios+Ki67+ regulatory CD4 T cells (Tregs). In these patients, strongly enhanced suppressive functions Tregs, mainly a contact-dependent manner. Paradoxically, concurrent...
Cancer-specific splice variants gain significant interest as they generate neo-antigens that could be targeted by immune cells. CD20, a membrane antigen broadly expressed in mature B cells and cell lymphomas, is subject to an alternative splicing named D393-CD20 leading loss of expression the spliced isoform. detectable transformed upregulated various lymphoma In this study, we show translated malignant specific CD4 T producing IFN-γ are present B-cell patients. Then, have investigated...
Abstract Understanding the mechanisms that enable cancer cells to metastasize is essential in preventing progression. Here we examine metabolic adaptations of metastasis-initiating (MICs) female breast and how those shape their metastatic phenotype. We find endogenous MICs depend on oxidative tricarboxylic acid cycle fatty usage. Sorting tumor based upon solely mitochondrial membrane potential or lipid storage sufficient at identifying MICs. further identify mitochondrially-generated citrate...
Natural killer (NK) cells are innate effector lymphocytes widely involved in cancer immunosurveillance. In this study, we described three circulating NK cell subsets patients with non-small lung (NSCLC). Compared to healthy donors (HD), lower rate of the cytotoxic CD56dim CD16+ was found NSCLC (76.1% vs 82.4%, P = 0.0041). contrast, CD56bright similar between and HD. We showed a higher subset CD16− phenotype (16.7% 9.9% 0.0001). The degranulation property cytokines production were mainly...
Cumulative evidence supports that CD4(+) Th1 cells play a key role in antitumor immunity. We previously reported the presence of spontaneous HLA-DR-restricted responses against telomerase reverse transcriptase (TERT) various cancers by using promiscuous HLA-DR epitopes. Here, we described novel highly immunogenic HLA-DP4-binding epitopes from TERT named TERT541-555, TERT573-587, TERT613-627 and TERT911-925 addressed question about immunoprevalence magnitude naturally occurring T cell...
Abstract Telomerase is a prototype-shared tumor Ag and represents an attractive target for anticancer immunotherapy. We have previously described promiscuous immunogenic HLA-DR–restricted peptides derived from human telomerase reverse transcriptase (hTERT) referred as universal cancer peptide (UCP). In nonsmall cell lung cancer, the presence of spontaneous UCP-specific CD4 T responses increases survival chemotherapy-responding patients. However, precise mechanisms hTERT’s uptake, processing,...
mTOR pathway inhibitors such as rapalogs represent a promising tool to induce functional memory CD8 T cells. In our study, we investigated the combination of temsirolimus with anticancer vaccines. Using various designs cancer vaccines (short and long peptides or B subunit Shiga toxin an antigen delivery vector) tumor models (melanoma, lung colon cancer), showed that administration efficiently decreased growth enhanced tumor‐specific T‐cell responses induced by vaccination. Furthermore, cells...
Accumulating evidence demonstrates the importance of CD4+ T cells in antitumor immune responses. Identifying promiscuous MHC class II-binding peptides derived from relevant tumor-associated antigens that specifically target helper vivo represent a powerful approach to fully exploit these for anticancer immunotherapy.
ABSTRACT The role of CD4 help during CD8 response and memory differentiation has been clearly demonstrated in different experimental models. However, the exact mechanisms remain largely unknown preclude replacement therapy to develop. Interestingly, studies have shown that administration an agonist aCD40ab can substitute vitro vivo, whereas targets this antibody elusive. In study, we address CD40 expression on APCs T cells using treatment mice. We demonstrate aCD40 antibodies synergetic...
// Laurie Rangan 1, 2 , Jeanne Galaine Romain Boidot 3 Mohamad Hamieh 4 Magalie Dosset Julie Francoual Laurent Beziaud Jean-René Pallandre 1 Elodie Lauret Marie Joseph Afag Asgarova ,Christophe Borg 2, 5 Talal Al Saati 6 Yann Godet Jean Baptiste Latouche 7 Séverine Valmary-Degano 8 and Olivier Adotévi University Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-gGreffon-Tumeur, Ingénierie Cellulaire et Génique, F-25000 Besançon, France LabEx LipSTIC, Platform for Transfer...
e22113 Background: Everolimus has demonstrated activity in the treatment of metastastic renal cell carcinoma (mRCC) after failure VEGF-targeted tyrosine kinase inhibitor. However, accumulating evidence highlights a central role for mTOR pathway T activation and differentiation. For example, inhibition can induce regulatory CD4 cells (Treg), which promote immunosuppression required to prevent transplant rejection. Furthermore, recent studies have reported that blocking also stimulate...
<div>Abstract<p>The rapalogs everolimus and temsirolimus that inhibit mTOR signaling are used as antiproliferative drugs in several cancers. Here we investigated the influence of rapalogs-mediated immune modulation on their antitumor efficacy. Studies metastatic renal cell carcinoma patients showed promoted high expansion FoxP<sub>3</sub><sup>+</sup>Helios<sup>+</sup>Ki67<sup>+</sup> regulatory CD4 T cells...
<p>This file contains the supplementary material and methods</p>
<p>This file contains the legends for supplementary figures</p>
<p>This file contains in vivo studies renal and mammary tumor models: Supplementary figure 6</p>
<p>PDF file - 38K, Comparison of T-cell help mediated by UCP2 and a HTLV-1 Tax-derived peptide on self/TERT pY988 specific CTL response</p>
<p>PDF file - 57K, UCPs mediated helper effect on CTLs in other models of vaccinations</p>
<p>PDF file - 26K, UCP2 specific CD4 T cells recognize the mTERT-derived counterpart peptide p568</p>